Table 1.
Patient characteristics
| Patient Characteristics | Distribution, n (%) | |
|---|---|---|
| Gender | Female | 19 (83) |
| Male | 4 (17) | |
| Age (years) | Median (range) | 64 (37-76) |
| < 45 | 2 (8) | |
| 45 - 64 | 10 (44) | |
| ≥ 65 | 11 (48) | |
| KPS | 90 | 10 (43) |
| 80 | 13 (57) | |
| Histologic type | Papillary | 19 (83) |
| Poorly differentiated | 4 (17) | |
| Recurrence | Primary tumor | 8 (35) |
| Recurrent tumor | 15 (65) | |
| T stage at initial diagnosis | T1-2 | 1 (4) |
| T3 | 14 (61) | |
| T4 | 8 (35) | |
| N stage at initial diagnosis | N0 | 4 (17) |
| N1a | 10 (44) | |
| N1b | 9 (39) | |
| AJCC Stage at initial diagnosis | I-II | 3 (12) |
| III | 10 (44) | |
| IVA | 10 (44) | |
| T stage at pre-EBRT | T0-2 | 3 (13) |
| T3 | 3 (13) | |
| T4 | 17 (74) | |
| N stage at pre-EBRT | N0 | 3 (13) |
| N1a | 4 (17) | |
| N1b | 16 (70) | |
| AJCC Stage at pre-EBRT | I-III | 3 (13) |
| IVA | 14 (61) | |
| IVB | 1 (4) | |
| IVC | 5 (22) | |
| Tg* level(ng/mL) | Median (range) | 10 (0.2-1411) |
| < 10 | 11 (48) | |
| ≥ 10 | 12 (52) | |
| Thyroid surgery | Subtotal thyroidectomy | 4 (17) |
| Total thyroidectomy | 19 (83) | |
| Lymph node surgery | CND | 6 (26) |
| CND+Unilateral SND/MRND | 14 (61) | |
| CND+Bilateral SND/MRND | 3 (13) | |
| Postoperative residuum | No | 3 (13) |
| Microscopic | 2 (9) | |
| Macroscopic | 18 (78) | |
| Radioiodine treatment | No | 4 (17) |
| Yes | 19 (83) | |
| EBRT volume | Limited field | 11 (48) |
| Elective field | 12 (52) | |
| EBRT dose (EQD2, Gy) | Median (range) | 62.5 (60-69) |
Abbreviation: KPS = Karnofsky performance status; AJCC, American Joint Committee on Cancer; EBRT, external beam radiotherapy; Tg* = pre-EBRT serum thyroglobulin; CND = central compartmental neck dissection; SND = selective neck dissection; MRND = modified radical neck dissection; EQD2, biologically equivalent dose in 2 Gy fractions using a linear quadratic model (α/β ratio for acute effects on normal tissues and tumors = 10).